Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia?

Diabetes, Obesity and Metabolism

Volumn 20, Issue 6, 2018, Pages 1337-1341

  Khunti, Kamlesh ^a   Kosiborod, Mikhail ^b   Ray, Kausik K ^c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

blood pressure; glycaemic control; legacy effect; lipids

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; PLACEBO; PRAVASTATIN;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; BLOOD; CLINICAL PRACTICE; COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; EVIDENCE BASED MEDICINE; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; MORTALITY; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE;

CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RISK FACTORS;

EID: 85046726993     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13243     Document Type: Review

References (30)

1. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015;38:49-57.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
4. Holman RR, Paul SK, Bethal MA, Neil AW, Matthews DR. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
5. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392-1406.
6. Agrawal L, Azad N, Bahn GD, et al. Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia. 2018;61:295-299.
7. Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like petide-1 receptor agonist exenatide or insulin with cardivascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol. 2015;14:10.
8. Davies TME, Chubb SAP, Bruce DG, Davies WA. Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Obes Metab. 2016;18:598-606.
9. Parving HH, Smidt UM, Andersen AR, Svendsen P. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet. 1983;321:1175-1178.
10. Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension. 2010;56:1060-1068.
11. Kostis WJ, Moreyra AE, Cheng JQ, Dobrzynski JM, Kostis JB. Continuation of mortality reduction after the end of randomized therapy in clinical trials of lipid-lowering therapy. J Clin Lipidol. 2011;5:97-104.
12. Sever PS, Chaang CL, Gupta AK, Whitehouse A, Poulter NR, ASCOT Investigators. The Anglo-Scandinavian cardiac outcomes trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. Eur Heart J. 2011;32:2525-2532.
13. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow up of west of Scotland coronary prevention study. Circulation. 2016;133:1073-1080.
14. Gaede P, Vedal P, Parving HH, Pederson O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353:617-622.
15. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393.
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
17. Gaede P, Oellgaard J, Carstensen B. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298-2307.
18. Oellgaard J, Gaede P, Rossing P, Persson F, Parving H-H, Pederson O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits. Kidney Int. 2017;91:982-988.
19. Reddy MA, Zhang E, Natarajan R. Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia. 2015;58:443-455.
20. Ceriello A. The “metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94:410-415.
21. Bhargava SK, Sachdev HS, Fall CHD, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 2004;350:865-875.
22. Volpe M, Cosentino F, Tocci G, Palano F, Paneni F. Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep. 2011;13:318-324.
23. Zhang L. Metabolic memory: mechanisms and implications for diabetic retinopathy. Diabetes Res Clin Pract. 2012;96:286-293.
24. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipprotein cholesterol beginning early in life on the risk of coronary heart disease. JACC. 2012;60:2631-2639.
25. Okonofua EC, Simpson KN, Jesir A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the health people 2010 blood pressure control goals. Hypertension. 2006;47:345-351.
26. Chiang CE, Ferrières J, Gotcheva NN, et al. Suboptimal control of lipid levels: results from 29 countries participating in the centralized pan-regional surveys on the undertreatment of hypercholesterolaemia (CEPHUS). J Atheroscler Thromb. 2016;23:567-587.
27. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes. Diabetes Care. 2013;36:3411-3417.
28. Wilmot KA, O'Flaherty M, Capewell S, et al. Coronary heart disease mortality declines in the united states from 1979 through 2011: evidence for stagnation in young adults, especially women. Circulation. 2015;132:997-1002.
29. Group TDCaCTEoDIaCR. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
30. Orchard T. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015;313:45-53.